Hawthorne Effect Strengthens Leadership and Board of Directors

New CEO and board appointees from Labcorp, CVS Health and Northpond Ventures join to fuel company’s rapid growth and leadership position within the clinical trials market

SAN FRANCISCO- Feb. 28, 2024

 In January, Hawthorne Effect, a leader in technology-enabled mobile clinical research, announced the appointment of Josh Rose as new CEO.  Josh is a clinical trial industry veteran with over 14 years of executive leadership experience with blue chip companies such as IQVIA, CVS Health and others.  Rose’s expertise combines market strategy, M&A, new business growth and operations, and track record of commercial success, is perfectly matched to further accelerate Hawthorne Effects growth.  

“I’ve always been attracted to companies that have a unique approach to solving significant industry challenges,” said Rose.  “Driving greater patient access and participation in clinical trials is one of the most pressing challenges for pharma sponsors.  Hawthorne Effect’s pioneering approach to rapidly enabling study visits in the patient’s home at attractive unit economics, eliminates the barrier for greater adoption of mobile visits in hybrid or any clinical trial.”

Hawthorne Effect has also strengthened its board of directors with three new appointments who together bring over 50 years of clinical trials, biotechnology and patient services experience.  New directors include Jon DiVincenzo, EVP & President, Central Laboratories Services and International, Labcorp, Tony Clapsis, former SVP at CVS Health, and Ingo Chakravarty, operating partner at Northpond Ventures  and former CEO of Mesa (sold to Fisher Scientific).  “Transforming clinical trials is not about flashy tech and buzz words.  It’s brass-tacks operational delivery with practical solutions that work,” said Tony Clapsis.  “With the industry’s largest network of GCP trained independent clinicians, enabled by a novel tech approach, Hawthorne Effect rapidly matches and schedules mobile trial visits anywhere.” New members join current board members Jodi Akin (Hawthorn Effect founder) and Lucy Coassin. 

Labcorp and Hawthorne Effect recently announced a strategic partnership to increase patient diversity, decrease site burden, and accelerate enrollment and clinical study timelines. 

“At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities,” said DiVincenzo. “Through this collaboration, we look forward to combining Labcorp’s global laboratory network and logistics capabilities with Hawthorne Effect’s digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.”

About Hawthorne Effect

Hawthorne Effect is a complete clinical trials solution integrating technology and people to transform the clinical trials industry. Its technology-enabled platform and distributed network of certified medical professionals, Hawthorne Heroes, enable patients and clinicians to participate in trials within their trusted community. Its solution accelerates clinical research and generates evidence that makes clinical trials accessible and convenient while delivering meaningful and high-quality clinical assessments. Since launching in 2015, Hawthorne Effect has helped complete 76 trials and worked with industry leaders within medtech, biopharma, retail health and healthcare systems. Learn more about Hawthorne Effect by visiting

    More News

    Discover how we can help your trial

    Let’s discuss how Hawthorne Effect can take your clinical trial to completion and approval with access and accuracy